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From Adequate Evidence to Optimal Evidence
Leslee Shaw, PHD,* Jagat Narula, MD, PHD†In this issue of iJACC, Dilsizian and Taillefer (1)
offer a historical tour highlighting radiopharma-
ceutical developments for cardiac applications in
nuclear medicine. This review features the staged
developments in the field of nuclear cardiology
from initial thallium-201 applications to the upcom-
ing promise of the new F-18 agent, Flurpiridaz. As
noted in this review, the data with positron emis-
sion (PET) and single-photon emission computed
(SPECT) tomography has been unfolding over
the past few years with more emphasis on prog-
nosis (2,3), risk stratification with myocardial flow
reserve (3,4), radiation dose reduction techniques
(5), new cameras (6,7), new protocols (8), and,
now, new isotopes (9–11). Basically, the whole
field has revamped over the past few years! To-
day’s practice of nuclear cardiology has little re-
semblance to the planar imaging days where im-
ages were indubitably described as unclear medicine.
Clinical advances of fast speed, low-radiation expo-
sure, and enhanced resolution are now possible with
nuclear cardiology procedure and provide an im-
proved diverse set of tools to the practicing nuclear
cardiologist. This review highlights the research de-
velopments from the point of regulatory approval
and provides a balanced evaluation of the strengths
and limitations of each isotope.
Flurpiridaz is an exciting development in the
field with preliminary data showing improvements
in diagnostic accuracy and, importantly, a suffi-
ciently long half life allowing for regional cyclo-
tron production (10). This agent has also demon-
strated the ability to allow for both pharmacologic
stress and exercise in contrast to the current PET
agents that may only be used with pharmacologic
stress. The “talk on the street” within the nuclear
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the †Mount Sinai School of Medicine, New York, New York.cardiology community is that Flurpiridaz PET
images have better defect contrast than SPECT
images, which would be expected to result in im-
proved diagnostic and prognostic accuracy. The
introduction of new radioisotopes is an exciting
development in the field of nuclear cardiology and
provides another important advancement in the
field and enhanced armamentarium for highly ac-
curate detection of coronary disease and predic-
tion of ensuing patient risk.
Yet, this review is published in an era where
we have seen tremendous tumult in the field of
cardiac imaging where, for nuclear cardiology,
sizeable payment reductions and utilization man-
agement efforts have led to declining utilization
patterns (3,12). Moreover, there is a call from
health care advocacy and policy experts for higher
quality evidence including comparative effective-
ness research in order to guide and justify proce-
dural use (11,13). So, the question to ask is
whether in today’s imaging marketplace, can we
expect that new developments will provide the
same “magic bullet” effect that they did in years
past? When Tc-99m sestamibi was approved, the
ensuing research led to a dramatic double digit
annual growth rate in the field of nuclear cardiol-
ogy (3). Given the current, cautious state of the
field of nuclear cardiology and the high threshold
required from Centers for Medicare and Medicaid
Services’ coverage with evidence development, it
remains arguable whether these new developments
can catapult the field to the grander days of un-
constrained growth.
We are seeing an ever-increasing schism be-
tween the requirements for regulatory approval
and the new calls for comparative effectiveness ev-
idence for nuclear cardiology compared to other
imaging techniques. The call for comparative re-
search was initially led by the Institute of Medi-
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1293cine reports on quality in health care (14) and,
more recently, with funding announcements from
the Agency for Healthcare Research and Quality
and the Patient-Centered Outcomes Research In-
stitute. A “sea change” is required between industry
drug/device development and comparative effective-
ness research in order to drive patient-centered, op-
timal application of imaging procedures (15,16).
It remains contested as to whether there would be
sufficient industry financial resources in order to
provide necessary and sufficient comparative effec-state spect technology: Fast and furious.
J Nuclear Cardiol 2010;17:890–6.
1
1
et al. Phase I, first-
BMS747158, a nproval process or as part of post-marketing re-
search. Some argue that the current focus on the
high evidentiary standards of quality or effectiveness
research will lead to a stifling of innovation on the
part of academic and industry researchers (16).
What will promulgate the transformation from
adequate evidence to optimal, patient-centered ef-
fectiveness evidence is currently unknown. But, it
is fair to state that this evidence is essential to re-
vealing the promise of imaging as a critical link to
guiding therapeutic management and improvingtiveness evidence either within the regulatory ap- patient outcomes.R E F E R E N C E S
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